Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)

ClinicalTrials.gov ID: NCT04148391

Public ClinicalTrials.gov record NCT04148391. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 13, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia

Study identification

NCT ID
NCT04148391
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Aptinyx
Industry
Enrollment
99 participants

Conditions and interventions

Eligibility (public fields only)

Age range
50 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 13, 2019
Primary completion
Dec 29, 2022
Completion
Dec 29, 2022
Last update posted
Oct 26, 2022

2019 – 2022

United States locations

U.S. sites
26
U.S. states
13
U.S. cities
23
Facility City State ZIP Site status
Aptinyx Clinical Site Scottsdale Arizona 85258
Aptinyx Clinical Site Fresno California 93710
Aptinyx Clinical Site Simi Valley California 93065
Aptinyx Clinical Site Boca Raton Florida 33486
Aptinyx Clinical Site Bradenton Florida 34209
Aptinyx Clinical Site Miami Florida 33122
Aptinyx Clinical Site Miami Florida 33165
Aptinyx Clinical Site Miami Florida 33173
Aptinyx Clinical Site Miami Florida 33176
Aptinyx Clinical Site Miami Lakes Florida 33016
Aptinyx Clinical Site Orlando Florida 32819
Aptinyx Clinical Site Port Charlotte Florida 33980
Aptinyx Clinical Site Port Orange Florida 32127
Aptinyx Clinical Site Sunrise Florida 33351
Aptinyx Clinical Site Decatur Georgia 30030
Aptinyx Clinical Site Farmington Hills Michigan 48334
Aptinyx Clinical Site Golden Valley Minnesota 55427
Aptinyx Clinical Site Toms River New Jersey 08755
Aptinyx Clinical Site Poughkeepsie New York 12601
Aptinyx Clinical Site Asheville North Carolina 28806
Aptinyx Clinical Site Dayton Ohio 45459
Aptinyx Clinical Site Tulsa Oklahoma 74136
Aptinyx Clinical Site Round Rock Texas 78681
Aptinyx Clinical Site Sugar Land Texas 77478
Aptinyx Clinical Site Bellevue Washington 98007
Aptinyx Clinical Site Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04148391, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 26, 2022 · Synced Sep 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04148391 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →